Skip to main content
Login
Contact
Subscribe
Search form
Search
The Daily Times Leader
Click for weather forecast
Home
Forms
News
Sports
Classifieds
Obituaries
Entertainment
Local Guide
Special Sections
Talking About...
Photos
Videos
Games
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
News releases from Aerie Pharmaceuticals, Inc.
< Previous
1
2
3
4
5
6
7
8
9
Next >
Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 07, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma
March 30, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase
March 11, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals to Participate in the Oppenheimer 31st Annual Virtual Healthcare Conference
March 11, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
February 25, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
February 22, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
February 18, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
January 11, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union
November 13, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference
November 10, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
November 05, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
October 29, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries
October 28, 2020
Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered into an exclusive development and commercialization...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020
October 27, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease
September 29, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical Trial in Europe
September 24, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02%
September 15, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
September 08, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
August 06, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020
July 30, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion
July 27, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors
June 11, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
May 06, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference
May 05, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020
April 29, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19
April 09, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
April 07, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference
February 24, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update
February 20, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
Aerie Pharmaceuticals Announces Appointment of Nina Ohara, PharmD, M.B.A, as Director, Marketing and Gregory Jones, CPA, as Director, Tax
February 18, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...
Tickers
AERI
From
Business Wire News Releases
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.